Company Filing History:
Years Active: 2019-2023
Title: Matthieu Broussas: Innovator in Cancer Treatment
Introduction
Matthieu Broussas is a prominent inventor based in Seyssel, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of antibody-drug conjugates. With a total of 7 patents to his name, Broussas is recognized for his dedication to advancing medical science.
Latest Patents
Among his latest patents is the development of an IGF-1R antibody-drug conjugate, which is designed for the treatment of cancer. This invention relates to an antibody-drug conjugate capable of binding to IGF-1R, comprising an antibody conjugated to drugs derived from dolastatin 10 and auristatins. Additionally, he has patented an IGF-1R antibody that serves as an addressing vehicle for cancer treatment. This monoclonal antibody is capable of binding to IGF-1R and inducing its internalization into cells, allowing for targeted delivery of anti-cancer compounds.
Career Highlights
Broussas has worked with notable companies in the pharmaceutical industry, including Pierre Fabre Medicament and Pierre Fabre Médicament. His work has focused on developing innovative solutions for cancer therapies, showcasing his commitment to improving patient outcomes.
Collaborations
Throughout his career, Matthieu Broussas has collaborated with esteemed colleagues such as Liliane Goetsch and Charlotte Beau-Larvor. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Matthieu Broussas stands out as a key figure in the field of cancer treatment innovation. His contributions through patents and collaborations highlight his commitment to advancing medical science and improving therapeutic options for patients.